Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 12, 2008, Pages 1776-1783

  Krebs, Alexander ^a   Wallaschofski, Henri ^a   Spilcke Liss, Elisabeth ^a   Kohlmann, Thomas ^a   Brabant, Georg ^b   Völzke, Henry ^a   Nauck, Matthias ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Assay; Evaluation; Growth hormone deficiency; Insulin like growth factor I (IGF I); Sensitivity; Specificity

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACCURACY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONE DETERMINATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL ASSAY; BLOOD CHEMICAL ANALYSIS; HUMANS; INSULIN-LIKE GROWTH FACTOR I;

EID: 57449103753     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.349     Document Type: Article

References (18)

1. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998;19:717-97.
2. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
3. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab 2000;85:3990-3.
4. Brabant G. Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. Eur J Endocrinol 2003;148(Suppl 2):S15-20.
5. Shalet SM, Toogood A, Rahim A, Brennan BM. The diagnosis of growth hormone deficiency in children and adults. Endocr Rev 1998;19:203-23.
6. Bereket A, Turan S, Omar A, Berber M, Ozen A, Akbenlioglu C, et al. Serum IGF-I and IGFBP-3 levels of Turkish children during childhood and adolescence: establishment of reference ranges with emphasis on puberty. Horm Res 2006;65:96-105.
7. Lofqvist C, Andersson E, Gelander L, Rosberg S, Blum WF, Albertsson WK. Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultaneously for the effect of gender, age, and puberty. J Clin Endocrinol Metab 2001;86:5870-6.
8. Lofqvist C, Andersson E, Gelander L, Rosberg S, Hulthen L, Blum WF, et al. Reference values for insulin-like growth factor-binding protein-3 (IGFBP-3) and the ratio of insulin-like growth factor-I to IGFBP-3 throughout childhood and adolescence. J Clin Endocrinol Metab 2005;90:1420-7.
9. Brabant G, von Zur MA, Wuster C, Ranke MB, Kratzsch J, Kiess W, et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 2003;60:53-60.
10. Friedrich N, Alte D, Volzke H, Spilcke-Liss E, Ludemann J, Lerch MM, et al. Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: results of the Study of Health in Pomerania (SHIP). Growth Horm IGF Res 2008;18:228-37.
11. Ranke MB, Osterziel KJ, Schweizer R, Schuett B, Weber K, Robbel P, et al. Reference levels of insulin-like growth factor I in the serum of healthy adults: comparison of four immunoassays. Clin Chem Lab Med 2003;41:1329-34.
12. Wallaschofski H, Saller B, Spilcke-Liss E, Lerch MM, Lohmann T, Eigenthaler M. Effects of growth hormone treatment on B-type natriuretic peptide as a marker of heart failure in adults with growth hormone deficiency. Horm Metab Res 2006;38:656-61.
13. Ito Y, Nakachi K, Imai K, Hashimoto S, Watanabe Y, Inaba Y, et al. Stability of frozen serum levels of insulin-like growth factor-I, insulin-like growth factor-II, insulin-like growth factor binding protein-3, transforming growth factor beta, soluble Fas, and superoxide dismutase activity for the JACC study. J Epidemiol 2005;15(Suppl 1):S67-73.
14. Harris TG, Strickler HD, Yu H, Pollak MN, Monrad ES, Travin MI, et al. Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3). Growth Horm IGF Res 2006;16:86-92.
15. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf) 2007;67:65-70.
16. Quarmby V, Quan C, Ling V, Compton P, Canova-Davis E. How much insulin-like growth factor I (IGF-I) circulates? Impact of standardization on IGF-I assay accuracy. J Clin Endocrinol Metab 1998;83:1211-6.
17. Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995;80:2534-42.
18. Clemmons DR. IGF-I assays: current assay methodologies and their limitations. Pituitary 2007;10:121-8.